Pascal Deschatelets - 09 Jun 2025 Form 4 Insider Report for Apellis Pharmaceuticals, Inc. (APLS)

Role: Chief Scientific Officer
Signature: /s/ David Watson, attorney-in-fact for Pascal Deschatelets
Issuer symbol: APLS
Transactions as of: 09 Jun 2025
Transactions value $: $1,599,675
Form type: 4
Filing time: 11 Jun 2025, 16:19:13
Previous filing: 22 May 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Deschatelets Pascal	Chief Scientific Officer	C/O APELLIS PHARMACEUTICALS, INC., 100 FIFTH AVENUE, 3RD FLOOR, WALTHAM	/s/ David Watson, attorney-in-fact for Pascal Deschatelets	11 Jun 2025	0001657720

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	APLS	Stock Option (Right to Buy)	Award	$1.6M	+82.5K		$19.39	82.5K	09 Jun 2025	Common Stock	82.5K	$19.39	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	This represents stock option award granted on June 9, 2025, which will vest over a two-year period. Specifically, 50% of the options will vest on each of the one-year and two-year anniversaries of the grant date, contingent upon continued service.